Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 2/20 | 0.43 |
| ▸ | DNTT | P04053 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2957305 | 0.98 | POLA1 (0.46) | POLA1DNTTPOLB | |
| SCHEMBL39811 | 0.95 | POLA1 (0.38) | POLA1DNTTPOLB | |
| SCHEMBL11341998 | 0.83 | POLA1 (0.47) | POLA1DNTTPOLB | |
| SCHEMBL3682762 | 0.81 | POLA1 (0.36) | POLA1DNTTPOLB | |
| SCHEMBL39621 | 0.81 | — | — | |
| SCHEMBL3039803 | 0.79 | POLA1 (0.34) | POLA1DNTTPOLB | |
| SCHEMBL3029195 | 0.78 | POLA1 (0.36) | POLA1DNTTPOLB | |
| SCHEMBL3042433 | 0.78 | POLA1 (0.36) | POLA1DNTTPOLB | |
| SCHEMBL3033173 | 0.78 | POLA1 (0.36) | POLA1DNTTPOLB | |
| SCHEMBL9007354 | 0.78 | POLA1 (0.36) | POLA1DNTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109475838-B | Functionalized particles with modified phase | 安捷伦科技有限公司 | 2022-05-03 | — | — | CN | disclosed |
| US-10618920-B2 | Functionalized particles having modified phases | AGILENT TECHNOLOGIES, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| EP-3463645-A1 | FUNCTIONALIZED PARTICLES HAVING MODIFIED PHASES | Agilent Technologies, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20170349612-A1 | FUNCTIONALIZED PARTICLES HAVING MODIFIED PHASES | AGILENT TECHNOLOGIES, INC. | 2017-12-07 | — | — | US | disclosed |
| WO-2017210223-A1 | FUNCTIONALIZED PARTICLES HAVING MODIFIED PHASES | AGILENT TECHNOLOGIES, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
| US-20100087351-A1 | Perfumes for Linear Citrus Release in Rinse-Off Systems | QUEST INTERNATIONAL SERVICES B.V. (NL) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618920-B2 | Functionalized particles having modified phases | PHOSPHO1, RAB5IF, FLNA | POLA1 944/4885DNTT 3341/4885POLB 1622/4885 |
| US-20170349612-A1 | FUNCTIONALIZED PARTICLES HAVING MODIFIED PHASES | PHOSPHO1, RAB5IF, FLNA | POLA1 944/4885DNTT 3341/4885POLB 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.